CN116723851A - 白介素-18变体和使用方法 - Google Patents
白介素-18变体和使用方法 Download PDFInfo
- Publication number
- CN116723851A CN116723851A CN202180089105.7A CN202180089105A CN116723851A CN 116723851 A CN116723851 A CN 116723851A CN 202180089105 A CN202180089105 A CN 202180089105A CN 116723851 A CN116723851 A CN 116723851A
- Authority
- CN
- China
- Prior art keywords
- polypeptide
- seq
- variant
- stabilized
- cases
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000003810 Interleukin-18 Human genes 0.000 title claims abstract description 809
- 108090000171 Interleukin-18 Proteins 0.000 title claims abstract description 809
- 238000000034 method Methods 0.000 title claims abstract description 86
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 178
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 166
- 229920001184 polypeptide Polymers 0.000 claims abstract description 159
- 239000000203 mixture Substances 0.000 claims abstract description 56
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 6
- 102220470467 Adenosine 5'-monophosphoramidase HINT2_C38S_mutation Human genes 0.000 claims description 439
- 230000035772 mutation Effects 0.000 claims description 309
- 108010070145 interleukin-18 binding protein Proteins 0.000 claims description 146
- 102000044166 interleukin-18 binding protein Human genes 0.000 claims description 146
- 210000004027 cell Anatomy 0.000 claims description 119
- 108090000623 proteins and genes Proteins 0.000 claims description 104
- 108010017537 Interleukin-18 Receptors Proteins 0.000 claims description 88
- 102000004557 Interleukin-18 Receptors Human genes 0.000 claims description 88
- 102220517454 DDIT3 upstream open reading frame protein_C68Y_mutation Human genes 0.000 claims description 87
- 102220283780 rs1555750712 Human genes 0.000 claims description 87
- 102220214526 rs1060502912 Human genes 0.000 claims description 85
- 102000004169 proteins and genes Human genes 0.000 claims description 84
- 235000018102 proteins Nutrition 0.000 claims description 83
- 206010028980 Neoplasm Diseases 0.000 claims description 82
- 239000003795 chemical substances by application Substances 0.000 claims description 77
- 230000027455 binding Effects 0.000 claims description 66
- -1 41BB Proteins 0.000 claims description 60
- 235000001014 amino acid Nutrition 0.000 claims description 57
- 150000007523 nucleic acids Chemical class 0.000 claims description 50
- 102200149714 rs113604459 Human genes 0.000 claims description 47
- 102000039446 nucleic acids Human genes 0.000 claims description 46
- 108020004707 nucleic acids Proteins 0.000 claims description 46
- 238000011282 treatment Methods 0.000 claims description 44
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 38
- 102220557454 Mitochondrial 2-oxoglutarate/malate carrier protein_C68V_mutation Human genes 0.000 claims description 36
- 150000001413 amino acids Chemical group 0.000 claims description 36
- 239000000427 antigen Substances 0.000 claims description 32
- 108091007433 antigens Proteins 0.000 claims description 32
- 102000036639 antigens Human genes 0.000 claims description 32
- 201000010099 disease Diseases 0.000 claims description 32
- 201000011510 cancer Diseases 0.000 claims description 30
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 26
- 210000000822 natural killer cell Anatomy 0.000 claims description 26
- 102000004127 Cytokines Human genes 0.000 claims description 25
- 108090000695 Cytokines Proteins 0.000 claims description 25
- 239000002773 nucleotide Substances 0.000 claims description 25
- 125000003729 nucleotide group Chemical group 0.000 claims description 25
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims description 23
- 238000003556 assay Methods 0.000 claims description 23
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims description 23
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims description 22
- 230000002829 reductive effect Effects 0.000 claims description 22
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 claims description 21
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 claims description 21
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 claims description 21
- 102000002669 Small Ubiquitin-Related Modifier Proteins Human genes 0.000 claims description 21
- 108010043401 Small Ubiquitin-Related Modifier Proteins Proteins 0.000 claims description 21
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 claims description 20
- 230000014509 gene expression Effects 0.000 claims description 18
- 108020001507 fusion proteins Proteins 0.000 claims description 17
- 102000037865 fusion proteins Human genes 0.000 claims description 17
- 102220477448 YY1-associated factor 2_S105D_mutation Human genes 0.000 claims description 16
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 claims description 16
- 108010074708 B7-H1 Antigen Proteins 0.000 claims description 15
- 102100038078 CD276 antigen Human genes 0.000 claims description 15
- 101000708016 Caenorhabditis elegans Sentrin-specific protease Proteins 0.000 claims description 15
- 101000868279 Homo sapiens Leukocyte surface antigen CD47 Proteins 0.000 claims description 15
- 102100032913 Leukocyte surface antigen CD47 Human genes 0.000 claims description 15
- 101001068133 Homo sapiens Hepatitis A virus cellular receptor 2 Proteins 0.000 claims description 14
- 101000611936 Homo sapiens Programmed cell death protein 1 Proteins 0.000 claims description 14
- 102100037850 Interferon gamma Human genes 0.000 claims description 14
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 claims description 14
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims description 14
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 claims description 13
- 230000001580 bacterial effect Effects 0.000 claims description 13
- 208000015181 infectious disease Diseases 0.000 claims description 13
- 239000003112 inhibitor Substances 0.000 claims description 13
- 239000008194 pharmaceutical composition Substances 0.000 claims description 13
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims description 12
- 102000001301 EGF receptor Human genes 0.000 claims description 12
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims description 12
- 101000884279 Homo sapiens CD276 antigen Proteins 0.000 claims description 12
- 101000863873 Homo sapiens Tyrosine-protein phosphatase non-receptor type substrate 1 Proteins 0.000 claims description 12
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 claims description 12
- 102100029948 Tyrosine-protein phosphatase non-receptor type substrate 1 Human genes 0.000 claims description 12
- 239000012651 immune agonist Substances 0.000 claims description 12
- 229940044680 immune agonist Drugs 0.000 claims description 12
- 102220420324 rs773113395 Human genes 0.000 claims description 12
- 102000003298 tumor necrosis factor receptor Human genes 0.000 claims description 12
- 102100037435 Antiviral innate immune response receptor RIG-I Human genes 0.000 claims description 11
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 claims description 11
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims description 11
- 102100038929 V-set domain-containing T-cell activation inhibitor 1 Human genes 0.000 claims description 11
- 102220417886 c.169C>G Human genes 0.000 claims description 11
- 108060003951 Immunoglobulin Proteins 0.000 claims description 10
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims description 10
- 102220602509 Small integral membrane protein 1_M51K_mutation Human genes 0.000 claims description 10
- 102000018358 immunoglobulin Human genes 0.000 claims description 10
- 208000030159 metabolic disease Diseases 0.000 claims description 10
- 108010065524 CD52 Antigen Proteins 0.000 claims description 9
- 102100031940 Epithelial cell adhesion molecule Human genes 0.000 claims description 9
- 102220576078 HLA class I histocompatibility antigen, B alpha chain_Q56L_mutation Human genes 0.000 claims description 9
- 101000920667 Homo sapiens Epithelial cell adhesion molecule Proteins 0.000 claims description 9
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims description 9
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims description 9
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims description 9
- 238000013019 agitation Methods 0.000 claims description 9
- 238000000746 purification Methods 0.000 claims description 9
- 102100029822 B- and T-lymphocyte attenuator Human genes 0.000 claims description 8
- 102100038080 B-cell receptor CD22 Human genes 0.000 claims description 8
- 102100024263 CD160 antigen Human genes 0.000 claims description 8
- 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 claims description 8
- 101000864344 Homo sapiens B- and T-lymphocyte attenuator Proteins 0.000 claims description 8
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 claims description 8
- 101000761938 Homo sapiens CD160 antigen Proteins 0.000 claims description 8
- 101000914324 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 5 Proteins 0.000 claims description 8
- 101000633784 Homo sapiens SLAM family member 7 Proteins 0.000 claims description 8
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 claims description 8
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 claims description 8
- 101000955999 Homo sapiens V-set domain-containing T-cell activation inhibitor 1 Proteins 0.000 claims description 8
- 102220489345 Melanoma-associated antigen 1_K53G_mutation Human genes 0.000 claims description 8
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims description 8
- 102100029198 SLAM family member 7 Human genes 0.000 claims description 8
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 claims description 8
- 239000012190 activator Substances 0.000 claims description 8
- 102220402269 c.152T>C Human genes 0.000 claims description 8
- 102200037006 rs1731017 Human genes 0.000 claims description 8
- 102220505238 5-hydroxytryptamine receptor 1B_P57K_mutation Human genes 0.000 claims description 7
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 claims description 7
- 102100026423 Adhesion G protein-coupled receptor E5 Human genes 0.000 claims description 7
- 102000003984 Aryl Hydrocarbon Receptors Human genes 0.000 claims description 7
- 108090000448 Aryl Hydrocarbon Receptors Proteins 0.000 claims description 7
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims description 7
- 239000002126 C01EB10 - Adenosine Substances 0.000 claims description 7
- 101150013553 CD40 gene Proteins 0.000 claims description 7
- 102100032912 CD44 antigen Human genes 0.000 claims description 7
- 102100036008 CD48 antigen Human genes 0.000 claims description 7
- 102100025221 CD70 antigen Human genes 0.000 claims description 7
- 108060001253 CD99 Proteins 0.000 claims description 7
- 102000024905 CD99 Human genes 0.000 claims description 7
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 7
- 102220575517 Glutamate receptor ionotropic, NMDA 2A_Q56A_mutation Human genes 0.000 claims description 7
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 claims description 7
- 101000718243 Homo sapiens Adhesion G protein-coupled receptor E5 Proteins 0.000 claims description 7
- 101000834898 Homo sapiens Alpha-synuclein Proteins 0.000 claims description 7
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims description 7
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 claims description 7
- 101000716130 Homo sapiens CD48 antigen Proteins 0.000 claims description 7
- 101000934356 Homo sapiens CD70 antigen Proteins 0.000 claims description 7
- 101001037256 Homo sapiens Indoleamine 2,3-dioxygenase 1 Proteins 0.000 claims description 7
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 claims description 7
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 claims description 7
- 101000998120 Homo sapiens Interleukin-3 receptor subunit alpha Proteins 0.000 claims description 7
- 101000984189 Homo sapiens Leukocyte immunoglobulin-like receptor subfamily B member 2 Proteins 0.000 claims description 7
- 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 claims description 7
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 claims description 7
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 claims description 7
- 101000884271 Homo sapiens Signal transducer CD24 Proteins 0.000 claims description 7
- 101000652359 Homo sapiens Spermatogenesis-associated protein 2 Proteins 0.000 claims description 7
- 101000831007 Homo sapiens T-cell immunoreceptor with Ig and ITIM domains Proteins 0.000 claims description 7
- 101000596234 Homo sapiens T-cell surface protein tactile Proteins 0.000 claims description 7
- 101000795117 Homo sapiens Triggering receptor expressed on myeloid cells 2 Proteins 0.000 claims description 7
- 101000801234 Homo sapiens Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 claims description 7
- 101000666896 Homo sapiens V-type immunoglobulin domain-containing suppressor of T-cell activation Proteins 0.000 claims description 7
- 102100040061 Indoleamine 2,3-dioxygenase 1 Human genes 0.000 claims description 7
- 102100026720 Interferon beta Human genes 0.000 claims description 7
- 102000003812 Interleukin-15 Human genes 0.000 claims description 7
- 108090000172 Interleukin-15 Proteins 0.000 claims description 7
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 claims description 7
- 102100033493 Interleukin-3 receptor subunit alpha Human genes 0.000 claims description 7
- 108010002586 Interleukin-7 Proteins 0.000 claims description 7
- 108010043610 KIR Receptors Proteins 0.000 claims description 7
- 102000002698 KIR Receptors Human genes 0.000 claims description 7
- 102220565496 Killer cell immunoglobulin-like receptor 2DL3_Q56E_mutation Human genes 0.000 claims description 7
- 102000017578 LAG3 Human genes 0.000 claims description 7
- 102100025583 Leukocyte immunoglobulin-like receptor subfamily B member 2 Human genes 0.000 claims description 7
- 102220506215 Lysophospholipid acyltransferase 5_M51R_mutation Human genes 0.000 claims description 7
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 claims description 7
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 claims description 7
- 102220496972 Platelet-activating factor acetylhydrolase 2, cytoplasmic_K53T_mutation Human genes 0.000 claims description 7
- 102100029740 Poliovirus receptor Human genes 0.000 claims description 7
- 102100038081 Signal transducer CD24 Human genes 0.000 claims description 7
- 102100024834 T-cell immunoreceptor with Ig and ITIM domains Human genes 0.000 claims description 7
- 102100035268 T-cell surface protein tactile Human genes 0.000 claims description 7
- 102100029678 Triggering receptor expressed on myeloid cells 2 Human genes 0.000 claims description 7
- 102100040247 Tumor necrosis factor Human genes 0.000 claims description 7
- 102100033728 Tumor necrosis factor receptor superfamily member 18 Human genes 0.000 claims description 7
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims description 7
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims description 7
- 102100038282 V-type immunoglobulin domain-containing suppressor of T-cell activation Human genes 0.000 claims description 7
- 229960005305 adenosine Drugs 0.000 claims description 7
- 239000000539 dimer Substances 0.000 claims description 7
- IJJVMEJXYNJXOJ-UHFFFAOYSA-N fluquinconazole Chemical compound C=1C=C(Cl)C=C(Cl)C=1N1C(=O)C2=CC(F)=CC=C2N=C1N1C=NC=N1 IJJVMEJXYNJXOJ-UHFFFAOYSA-N 0.000 claims description 7
- 108010048507 poliovirus receptor Proteins 0.000 claims description 7
- 102220226169 rs1064793657 Human genes 0.000 claims description 7
- 102220342210 rs1555392885 Human genes 0.000 claims description 7
- 102200067664 rs397507595 Human genes 0.000 claims description 7
- 230000008685 targeting Effects 0.000 claims description 7
- 101710127675 Antiviral innate immune response receptor RIG-I Proteins 0.000 claims description 6
- 102100038077 CD226 antigen Human genes 0.000 claims description 6
- 102100027207 CD27 antigen Human genes 0.000 claims description 6
- 102100031256 Cyclic GMP-AMP synthase Human genes 0.000 claims description 6
- 101710118064 Cyclic GMP-AMP synthase Proteins 0.000 claims description 6
- 108010007707 Hepatitis A Virus Cellular Receptor 2 Proteins 0.000 claims description 6
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 claims description 6
- 101000959794 Homo sapiens Interferon alpha-2 Proteins 0.000 claims description 6
- 101001054334 Homo sapiens Interferon beta Proteins 0.000 claims description 6
- 101000599940 Homo sapiens Interferon gamma Proteins 0.000 claims description 6
- 101001008874 Homo sapiens Mast/stem cell growth factor receptor Kit Proteins 0.000 claims description 6
- 101001109501 Homo sapiens NKG2-D type II integral membrane protein Proteins 0.000 claims description 6
- 101001084266 Homo sapiens Parathyroid hormone 2 receptor Proteins 0.000 claims description 6
- 101000831567 Homo sapiens Toll-like receptor 2 Proteins 0.000 claims description 6
- 101000669447 Homo sapiens Toll-like receptor 4 Proteins 0.000 claims description 6
- 101000669460 Homo sapiens Toll-like receptor 5 Proteins 0.000 claims description 6
- 101000669402 Homo sapiens Toll-like receptor 7 Proteins 0.000 claims description 6
- 108010034143 Inflammasomes Proteins 0.000 claims description 6
- 102100040018 Interferon alpha-2 Human genes 0.000 claims description 6
- 102000003814 Interleukin-10 Human genes 0.000 claims description 6
- 108090000174 Interleukin-10 Proteins 0.000 claims description 6
- 108010065637 Interleukin-23 Proteins 0.000 claims description 6
- 108010066979 Interleukin-27 Proteins 0.000 claims description 6
- 102000017761 Interleukin-33 Human genes 0.000 claims description 6
- 108010067003 Interleukin-33 Proteins 0.000 claims description 6
- 102000043129 MHC class I family Human genes 0.000 claims description 6
- 108091054437 MHC class I family Proteins 0.000 claims description 6
- 102100027754 Mast/stem cell growth factor receptor Kit Human genes 0.000 claims description 6
- 108010061593 Member 14 Tumor Necrosis Factor Receptors Proteins 0.000 claims description 6
- 102100022680 NKG2-D type II integral membrane protein Human genes 0.000 claims description 6
- 102100030869 Parathyroid hormone 2 receptor Human genes 0.000 claims description 6
- 101710196623 Stimulator of interferon genes protein Proteins 0.000 claims description 6
- 108010060818 Toll-Like Receptor 9 Proteins 0.000 claims description 6
- 102000002689 Toll-like receptor Human genes 0.000 claims description 6
- 108020000411 Toll-like receptor Proteins 0.000 claims description 6
- 102100024333 Toll-like receptor 2 Human genes 0.000 claims description 6
- 102100039360 Toll-like receptor 4 Human genes 0.000 claims description 6
- 102100039357 Toll-like receptor 5 Human genes 0.000 claims description 6
- 102100039390 Toll-like receptor 7 Human genes 0.000 claims description 6
- 102100033117 Toll-like receptor 9 Human genes 0.000 claims description 6
- 102100024587 Tumor necrosis factor ligand superfamily member 15 Human genes 0.000 claims description 6
- 108090000138 Tumor necrosis factor ligand superfamily member 15 Proteins 0.000 claims description 6
- 102100028785 Tumor necrosis factor receptor superfamily member 14 Human genes 0.000 claims description 6
- 108010074108 interleukin-21 Proteins 0.000 claims description 6
- 108010062802 CD66 antigens Proteins 0.000 claims description 5
- 102100024533 Carcinoembryonic antigen-related cell adhesion molecule 1 Human genes 0.000 claims description 5
- 208000035473 Communicable disease Diseases 0.000 claims description 5
- 101000952099 Homo sapiens Antiviral innate immune response receptor RIG-I Proteins 0.000 claims description 5
- 102000013462 Interleukin-12 Human genes 0.000 claims description 5
- 108010065805 Interleukin-12 Proteins 0.000 claims description 5
- 108010002350 Interleukin-2 Proteins 0.000 claims description 5
- 102000000588 Interleukin-2 Human genes 0.000 claims description 5
- 239000000872 buffer Substances 0.000 claims description 5
- 239000007857 degradation product Substances 0.000 claims description 5
- 208000035475 disorder Diseases 0.000 claims description 5
- 230000003571 opsonizing effect Effects 0.000 claims description 5
- FFILOTSTFMXQJC-QCFYAKGBSA-N (2r,4r,5s,6s)-2-[3-[(2s,3s,4r,6s)-6-[(2s,3r,4r,5s,6r)-5-[(2s,3r,4r,5r,6r)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-2-[(2r,3s,4r,5r,6r)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(e)-3-hydroxy-2-(octadecanoylamino)octadec-4-enoxy]oxan-3-yl]oxy-3-hy Chemical compound O[C@@H]1[C@@H](O)[C@H](OCC(NC(=O)CCCCCCCCCCCCCCCCC)C(O)\C=C\CCCCCCCCCCCCC)O[C@H](CO)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@]2(O[C@@H]([C@@H](N)[C@H](O)C2)C(O)C(O)CO[C@]2(O[C@@H]([C@@H](N)[C@H](O)C2)C(O)C(O)CO)C(O)=O)C(O)=O)[C@@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](CO)O1 FFILOTSTFMXQJC-QCFYAKGBSA-N 0.000 claims description 4
- BGFTWECWAICPDG-UHFFFAOYSA-N 2-[bis(4-chlorophenyl)methyl]-4-n-[3-[bis(4-chlorophenyl)methyl]-4-(dimethylamino)phenyl]-1-n,1-n-dimethylbenzene-1,4-diamine Chemical compound C1=C(C(C=2C=CC(Cl)=CC=2)C=2C=CC(Cl)=CC=2)C(N(C)C)=CC=C1NC(C=1)=CC=C(N(C)C)C=1C(C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 BGFTWECWAICPDG-UHFFFAOYSA-N 0.000 claims description 4
- 102100030310 5,6-dihydroxyindole-2-carboxylic acid oxidase Human genes 0.000 claims description 4
- 101100067974 Arabidopsis thaliana POP2 gene Proteins 0.000 claims description 4
- 108010008014 B-Cell Maturation Antigen Proteins 0.000 claims description 4
- 102000006942 B-Cell Maturation Antigen Human genes 0.000 claims description 4
- 101710149863 C-C chemokine receptor type 4 Proteins 0.000 claims description 4
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 claims description 4
- 102100032976 CCR4-NOT transcription complex subunit 6 Human genes 0.000 claims description 4
- 108091007741 Chimeric antigen receptor T cells Proteins 0.000 claims description 4
- 102100036466 Delta-like protein 3 Human genes 0.000 claims description 4
- 102100033553 Delta-like protein 4 Human genes 0.000 claims description 4
- 102000012804 EPCAM Human genes 0.000 claims description 4
- 101150084967 EPCAM gene Proteins 0.000 claims description 4
- 108010036395 Endoglin Proteins 0.000 claims description 4
- 102100037241 Endoglin Human genes 0.000 claims description 4
- 102100032031 Epidermal growth factor-like protein 7 Human genes 0.000 claims description 4
- 102100023600 Fibroblast growth factor receptor 2 Human genes 0.000 claims description 4
- 101710182389 Fibroblast growth factor receptor 2 Proteins 0.000 claims description 4
- 102100037362 Fibronectin Human genes 0.000 claims description 4
- 108010067306 Fibronectins Proteins 0.000 claims description 4
- 102100035139 Folate receptor alpha Human genes 0.000 claims description 4
- 101710088083 Glomulin Proteins 0.000 claims description 4
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 claims description 4
- 102000010956 Glypican Human genes 0.000 claims description 4
- 108050001154 Glypican Proteins 0.000 claims description 4
- 108050007237 Glypican-3 Proteins 0.000 claims description 4
- 102100030595 HLA class II histocompatibility antigen gamma chain Human genes 0.000 claims description 4
- 102100022623 Hepatocyte growth factor receptor Human genes 0.000 claims description 4
- 101000773083 Homo sapiens 5,6-dihydroxyindole-2-carboxylic acid oxidase Proteins 0.000 claims description 4
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 claims description 4
- 101000914321 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 7 Proteins 0.000 claims description 4
- 101000928513 Homo sapiens Delta-like protein 3 Proteins 0.000 claims description 4
- 101000872077 Homo sapiens Delta-like protein 4 Proteins 0.000 claims description 4
- 101100118549 Homo sapiens EGFR gene Proteins 0.000 claims description 4
- 101000921195 Homo sapiens Epidermal growth factor-like protein 7 Proteins 0.000 claims description 4
- 101001023230 Homo sapiens Folate receptor alpha Proteins 0.000 claims description 4
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 claims description 4
- 101001082627 Homo sapiens HLA class II histocompatibility antigen gamma chain Proteins 0.000 claims description 4
- 101000972946 Homo sapiens Hepatocyte growth factor receptor Proteins 0.000 claims description 4
- 101001046677 Homo sapiens Integrin alpha-V Proteins 0.000 claims description 4
- 101001018097 Homo sapiens L-selectin Proteins 0.000 claims description 4
- 101001039113 Homo sapiens Leucine-rich repeat-containing protein 15 Proteins 0.000 claims description 4
- 101000777628 Homo sapiens Leukocyte antigen CD37 Proteins 0.000 claims description 4
- 101000916644 Homo sapiens Macrophage colony-stimulating factor 1 receptor Proteins 0.000 claims description 4
- 101000628547 Homo sapiens Metalloreductase STEAP1 Proteins 0.000 claims description 4
- 101001133056 Homo sapiens Mucin-1 Proteins 0.000 claims description 4
- 101000623901 Homo sapiens Mucin-16 Proteins 0.000 claims description 4
- 101001126417 Homo sapiens Platelet-derived growth factor receptor alpha Proteins 0.000 claims description 4
- 101000617725 Homo sapiens Pregnancy-specific beta-1-glycoprotein 2 Proteins 0.000 claims description 4
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 claims description 4
- 101000835984 Homo sapiens SLIT and NTRK-like protein 6 Proteins 0.000 claims description 4
- 101000874179 Homo sapiens Syndecan-1 Proteins 0.000 claims description 4
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 claims description 4
- 101000904724 Homo sapiens Transmembrane glycoprotein NMB Proteins 0.000 claims description 4
- 101000679851 Homo sapiens Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims description 4
- 101000807561 Homo sapiens Tyrosine-protein kinase receptor UFO Proteins 0.000 claims description 4
- 102100022337 Integrin alpha-V Human genes 0.000 claims description 4
- 102100030703 Interleukin-22 Human genes 0.000 claims description 4
- 102000013264 Interleukin-23 Human genes 0.000 claims description 4
- 108020003285 Isocitrate lyase Proteins 0.000 claims description 4
- 102100033467 L-selectin Human genes 0.000 claims description 4
- 102100040645 Leucine-rich repeat-containing protein 15 Human genes 0.000 claims description 4
- 102100031586 Leukocyte antigen CD37 Human genes 0.000 claims description 4
- 102100030301 MHC class I polypeptide-related sequence A Human genes 0.000 claims description 4
- 102100028198 Macrophage colony-stimulating factor 1 receptor Human genes 0.000 claims description 4
- 102000001776 Matrix metalloproteinase-9 Human genes 0.000 claims description 4
- 108010015302 Matrix metalloproteinase-9 Proteins 0.000 claims description 4
- 102000003735 Mesothelin Human genes 0.000 claims description 4
- 108090000015 Mesothelin Proteins 0.000 claims description 4
- 102100026712 Metalloreductase STEAP1 Human genes 0.000 claims description 4
- 102100034256 Mucin-1 Human genes 0.000 claims description 4
- 102100023123 Mucin-16 Human genes 0.000 claims description 4
- 108010063954 Mucins Proteins 0.000 claims description 4
- 102100031789 Myeloid-derived growth factor Human genes 0.000 claims description 4
- 102100025246 Neurogenic locus notch homolog protein 2 Human genes 0.000 claims description 4
- 102100025247 Neurogenic locus notch homolog protein 3 Human genes 0.000 claims description 4
- 108090000772 Neuropilin-1 Proteins 0.000 claims description 4
- 108010029751 Notch2 Receptor Proteins 0.000 claims description 4
- 108010029756 Notch3 Receptor Proteins 0.000 claims description 4
- 102100030485 Platelet-derived growth factor receptor alpha Human genes 0.000 claims description 4
- 102100023832 Prolyl endopeptidase FAP Human genes 0.000 claims description 4
- 102100023068 Protein kinase C-binding protein NELL1 Human genes 0.000 claims description 4
- 101710100969 Receptor tyrosine-protein kinase erbB-3 Proteins 0.000 claims description 4
- 102100029986 Receptor tyrosine-protein kinase erbB-3 Human genes 0.000 claims description 4
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 claims description 4
- 102100025504 SLIT and NTRK-like protein 6 Human genes 0.000 claims description 4
- 101100123851 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) HER1 gene Proteins 0.000 claims description 4
- 102100035721 Syndecan-1 Human genes 0.000 claims description 4
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 claims description 4
- 101150057140 TACSTD1 gene Proteins 0.000 claims description 4
- 102000016946 TWEAK Receptor Human genes 0.000 claims description 4
- 108010014401 TWEAK Receptor Proteins 0.000 claims description 4
- 102100023935 Transmembrane glycoprotein NMB Human genes 0.000 claims description 4
- 102100036922 Tumor necrosis factor ligand superfamily member 13B Human genes 0.000 claims description 4
- 101710181056 Tumor necrosis factor ligand superfamily member 13B Proteins 0.000 claims description 4
- 102100037236 Tyrosine-protein kinase receptor UFO Human genes 0.000 claims description 4
- 108010065472 Vimentin Proteins 0.000 claims description 4
- 102000013127 Vimentin Human genes 0.000 claims description 4
- 238000010521 absorption reaction Methods 0.000 claims description 4
- MXKCYTKUIDTFLY-ZNNSSXPHSA-N alpha-L-Fucp-(1->2)-beta-D-Galp-(1->4)-[alpha-L-Fucp-(1->3)]-beta-D-GlcpNAc-(1->3)-D-Galp Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@H]2[C@@H]([C@@H](NC(C)=O)[C@H](O[C@H]3[C@H]([C@@H](CO)OC(O)[C@@H]3O)O)O[C@@H]2CO)O[C@H]2[C@H]([C@H](O)[C@H](O)[C@H](C)O2)O)O[C@H](CO)[C@H](O)[C@@H]1O MXKCYTKUIDTFLY-ZNNSSXPHSA-N 0.000 claims description 4
- 239000002738 chelating agent Substances 0.000 claims description 4
- 229940127276 delta-like ligand 3 Drugs 0.000 claims description 4
- 230000001939 inductive effect Effects 0.000 claims description 4
- 102000006495 integrins Human genes 0.000 claims description 4
- 108010044426 integrins Proteins 0.000 claims description 4
- 239000010445 mica Substances 0.000 claims description 4
- 229910052618 mica group Inorganic materials 0.000 claims description 4
- 230000003647 oxidation Effects 0.000 claims description 4
- 238000007254 oxidation reaction Methods 0.000 claims description 4
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 claims description 4
- 235000000346 sugar Nutrition 0.000 claims description 4
- 101150047061 tag-72 gene Proteins 0.000 claims description 4
- 210000005048 vimentin Anatomy 0.000 claims description 4
- 210000005253 yeast cell Anatomy 0.000 claims description 4
- 238000003776 cleavage reaction Methods 0.000 claims description 3
- 238000000338 in vitro Methods 0.000 claims description 3
- 102220246302 rs78979358 Human genes 0.000 claims description 3
- 102220075526 rs796052296 Human genes 0.000 claims description 3
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims description 2
- 229940045513 CTLA4 antagonist Drugs 0.000 claims description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims description 2
- FFEARJCKVFRZRR-UHFFFAOYSA-N L-Methionine Natural products CSCCC(N)C(O)=O FFEARJCKVFRZRR-UHFFFAOYSA-N 0.000 claims description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 2
- 229930195722 L-methionine Natural products 0.000 claims description 2
- 102000035195 Peptidases Human genes 0.000 claims description 2
- 108091005804 Peptidases Proteins 0.000 claims description 2
- 239000004365 Protease Substances 0.000 claims description 2
- 229930006000 Sucrose Natural products 0.000 claims description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 2
- 230000003750 conditioning effect Effects 0.000 claims description 2
- 230000001747 exhibiting effect Effects 0.000 claims description 2
- 229960004452 methionine Drugs 0.000 claims description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 2
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims description 2
- 229940068968 polysorbate 80 Drugs 0.000 claims description 2
- 229920000053 polysorbate 80 Polymers 0.000 claims description 2
- 102200145343 rs104894404 Human genes 0.000 claims description 2
- 102220234446 rs1064795967 Human genes 0.000 claims description 2
- 102200079914 rs193302884 Human genes 0.000 claims description 2
- 102220275444 rs760297349 Human genes 0.000 claims description 2
- 230000007017 scission Effects 0.000 claims description 2
- 239000005720 sucrose Substances 0.000 claims description 2
- 239000013603 viral vector Substances 0.000 claims description 2
- 102100024217 CAMPATH-1 antigen Human genes 0.000 claims 3
- 101710185679 CD276 antigen Proteins 0.000 claims 3
- 108010079206 V-Set Domain-Containing T-Cell Activation Inhibitor 1 Proteins 0.000 claims 3
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims 3
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims 3
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims 3
- 101000684503 Homo sapiens Sentrin-specific protease 3 Proteins 0.000 claims 2
- 208000032818 Microsatellite Instability Diseases 0.000 claims 2
- 102100023645 Sentrin-specific protease 3 Human genes 0.000 claims 2
- 238000004587 chromatography analysis Methods 0.000 claims 2
- 238000004191 hydrophobic interaction chromatography Methods 0.000 claims 2
- 244000309459 oncolytic virus Species 0.000 claims 2
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 claims 1
- 238000004255 ion exchange chromatography Methods 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 239000013600 plasmid vector Substances 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 238000010254 subcutaneous injection Methods 0.000 claims 1
- 239000007929 subcutaneous injection Substances 0.000 claims 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims 1
- 230000003442 weekly effect Effects 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 abstract description 10
- 230000007781 signaling event Effects 0.000 abstract description 4
- 101710205006 Interleukin-18-binding protein Proteins 0.000 abstract 1
- 102100035017 Interleukin-18-binding protein Human genes 0.000 abstract 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 160
- 241000282414 Homo sapiens Species 0.000 description 74
- 101000960954 Homo sapiens Interleukin-18 Proteins 0.000 description 71
- 102000043959 human IL18 Human genes 0.000 description 71
- 238000010494 dissociation reaction Methods 0.000 description 50
- 230000005593 dissociations Effects 0.000 description 50
- 230000000694 effects Effects 0.000 description 29
- 238000002474 experimental method Methods 0.000 description 29
- 241000699670 Mus sp. Species 0.000 description 26
- 229940024606 amino acid Drugs 0.000 description 23
- 238000009472 formulation Methods 0.000 description 18
- 230000004614 tumor growth Effects 0.000 description 18
- 108020004999 messenger RNA Proteins 0.000 description 17
- 102000053602 DNA Human genes 0.000 description 16
- 108020004414 DNA Proteins 0.000 description 16
- 229910052739 hydrogen Inorganic materials 0.000 description 16
- 150000001875 compounds Chemical class 0.000 description 15
- 230000004071 biological effect Effects 0.000 description 14
- 108091026890 Coding region Proteins 0.000 description 13
- 239000012634 fragment Substances 0.000 description 13
- 230000001965 increasing effect Effects 0.000 description 12
- 241001465754 Metazoa Species 0.000 description 11
- 241001529936 Murinae Species 0.000 description 11
- 208000024891 symptom Diseases 0.000 description 11
- 230000015572 biosynthetic process Effects 0.000 description 10
- 230000000875 corresponding effect Effects 0.000 description 10
- 235000018417 cysteine Nutrition 0.000 description 10
- 239000000463 material Substances 0.000 description 10
- 102000040430 polynucleotide Human genes 0.000 description 10
- 108091033319 polynucleotide Proteins 0.000 description 10
- 239000002157 polynucleotide Substances 0.000 description 10
- 102000005962 receptors Human genes 0.000 description 10
- 108020003175 receptors Proteins 0.000 description 10
- 229920002477 rna polymer Polymers 0.000 description 10
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 9
- 210000001519 tissue Anatomy 0.000 description 9
- 108060006698 EGF receptor Proteins 0.000 description 8
- 108010074328 Interferon-gamma Proteins 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- 230000004927 fusion Effects 0.000 description 8
- 239000000523 sample Substances 0.000 description 8
- 239000011780 sodium chloride Substances 0.000 description 8
- 238000006467 substitution reaction Methods 0.000 description 8
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 7
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 239000002299 complementary DNA Substances 0.000 description 7
- 229960004641 rituximab Drugs 0.000 description 7
- 241000239290 Araneae Species 0.000 description 6
- 102000013135 CD52 Antigen Human genes 0.000 description 6
- 239000002202 Polyethylene glycol Substances 0.000 description 6
- 238000002648 combination therapy Methods 0.000 description 6
- 210000002865 immune cell Anatomy 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 229960003130 interferon gamma Drugs 0.000 description 6
- 229920001223 polyethylene glycol Polymers 0.000 description 6
- 229920000642 polymer Polymers 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 238000001542 size-exclusion chromatography Methods 0.000 description 6
- 230000000087 stabilizing effect Effects 0.000 description 6
- 230000004083 survival effect Effects 0.000 description 6
- 238000002560 therapeutic procedure Methods 0.000 description 6
- 102100025137 Early activation antigen CD69 Human genes 0.000 description 5
- 101000934374 Homo sapiens Early activation antigen CD69 Proteins 0.000 description 5
- 108091028043 Nucleic acid sequence Proteins 0.000 description 5
- 230000000259 anti-tumor effect Effects 0.000 description 5
- 208000029742 colonic neoplasm Diseases 0.000 description 5
- 230000000295 complement effect Effects 0.000 description 5
- 229940127089 cytotoxic agent Drugs 0.000 description 5
- 230000002950 deficient Effects 0.000 description 5
- 238000010586 diagram Methods 0.000 description 5
- 238000000684 flow cytometry Methods 0.000 description 5
- 230000013595 glycosylation Effects 0.000 description 5
- 238000006206 glycosylation reaction Methods 0.000 description 5
- 230000036541 health Effects 0.000 description 5
- 230000000670 limiting effect Effects 0.000 description 5
- 208000002780 macular degeneration Diseases 0.000 description 5
- 201000001441 melanoma Diseases 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 238000002818 protein evolution Methods 0.000 description 5
- 230000011664 signaling Effects 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 5
- 229940124597 therapeutic agent Drugs 0.000 description 5
- 206010009944 Colon cancer Diseases 0.000 description 4
- 102000000704 Interleukin-7 Human genes 0.000 description 4
- 108091092195 Intron Proteins 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 4
- 208000000208 Wet Macular Degeneration Diseases 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 210000000577 adipose tissue Anatomy 0.000 description 4
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 4
- 239000002246 antineoplastic agent Substances 0.000 description 4
- 238000013378 biophysical characterization Methods 0.000 description 4
- 238000011260 co-administration Methods 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 229920001519 homopolymer Polymers 0.000 description 4
- 230000002163 immunogen Effects 0.000 description 4
- 239000002955 immunomodulating agent Substances 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 238000003780 insertion Methods 0.000 description 4
- 230000037431 insertion Effects 0.000 description 4
- 239000003446 ligand Substances 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 4
- 229960000575 trastuzumab Drugs 0.000 description 4
- 210000004881 tumor cell Anatomy 0.000 description 4
- 229910052727 yttrium Inorganic materials 0.000 description 4
- 206010006187 Breast cancer Diseases 0.000 description 3
- 208000026310 Breast neoplasm Diseases 0.000 description 3
- 238000011740 C57BL/6 mouse Methods 0.000 description 3
- 108091035707 Consensus sequence Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 102100039619 Granulocyte colony-stimulating factor Human genes 0.000 description 3
- 102000008100 Human Serum Albumin Human genes 0.000 description 3
- 108091006905 Human Serum Albumin Proteins 0.000 description 3
- 108010038807 Oligopeptides Proteins 0.000 description 3
- 102000015636 Oligopeptides Human genes 0.000 description 3
- 229930012538 Paclitaxel Natural products 0.000 description 3
- 108091093037 Peptide nucleic acid Proteins 0.000 description 3
- 108020004511 Recombinant DNA Proteins 0.000 description 3
- 241000700618 Vaccinia virus Species 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 229960000548 alemtuzumab Drugs 0.000 description 3
- 125000000539 amino acid group Chemical group 0.000 description 3
- 230000000692 anti-sense effect Effects 0.000 description 3
- 239000011324 bead Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 229960005395 cetuximab Drugs 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 229960001776 edrecolomab Drugs 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 238000012544 monitoring process Methods 0.000 description 3
- 210000001616 monocyte Anatomy 0.000 description 3
- 229960001592 paclitaxel Drugs 0.000 description 3
- 229960001972 panitumumab Drugs 0.000 description 3
- 230000036961 partial effect Effects 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 230000019491 signal transduction Effects 0.000 description 3
- 230000009870 specific binding Effects 0.000 description 3
- 230000006641 stabilisation Effects 0.000 description 3
- 238000011105 stabilization Methods 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 3
- 239000013598 vector Substances 0.000 description 3
- 230000009385 viral infection Effects 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- QZNNVYOVQUKYSC-JEDNCBNOSA-N (2s)-2-amino-3-(1h-imidazol-5-yl)propanoic acid;hydron;chloride Chemical compound Cl.OC(=O)[C@@H](N)CC1=CN=CN1 QZNNVYOVQUKYSC-JEDNCBNOSA-N 0.000 description 2
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- 102220554136 APC membrane recruitment protein 1_E42A_mutation Human genes 0.000 description 2
- 102220553782 APC membrane recruitment protein 1_K89A_mutation Human genes 0.000 description 2
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 108091033409 CRISPR Proteins 0.000 description 2
- 108090000994 Catalytic RNA Proteins 0.000 description 2
- 102000053642 Catalytic RNA Human genes 0.000 description 2
- 108091033380 Coding strand Proteins 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- 150000008574 D-amino acids Chemical class 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 2
- 239000005977 Ethylene Substances 0.000 description 2
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 2
- 108010093488 His-His-His-His-His-His Proteins 0.000 description 2
- 101000961065 Homo sapiens Interleukin-18 receptor 1 Proteins 0.000 description 2
- 108010047761 Interferon-alpha Proteins 0.000 description 2
- 102000006992 Interferon-alpha Human genes 0.000 description 2
- 108090000467 Interferon-beta Proteins 0.000 description 2
- 241000235058 Komagataella pastoris Species 0.000 description 2
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 2
- 241000712899 Lymphocytic choriomeningitis mammarenavirus Species 0.000 description 2
- 241000282567 Macaca fascicularis Species 0.000 description 2
- 108091005461 Nucleic proteins Proteins 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 description 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
- 108010018242 Transcription Factor AP-1 Proteins 0.000 description 2
- 102100023132 Transcription factor Jun Human genes 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 2
- 206010064930 age-related macular degeneration Diseases 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 239000004037 angiogenesis inhibitor Substances 0.000 description 2
- 230000003042 antagnostic effect Effects 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 239000012620 biological material Substances 0.000 description 2
- 239000012472 biological sample Substances 0.000 description 2
- 239000013592 cell lysate Substances 0.000 description 2
- 238000002659 cell therapy Methods 0.000 description 2
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 2
- 239000001679 citrus red 2 Substances 0.000 description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- 239000002254 cytotoxic agent Substances 0.000 description 2
- 231100000599 cytotoxic agent Toxicity 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 208000016097 disease of metabolism Diseases 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 206010017758 gastric cancer Diseases 0.000 description 2
- 229960000578 gemtuzumab Drugs 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 description 2
- 230000013632 homeostatic process Effects 0.000 description 2
- 229940072221 immunoglobulins Drugs 0.000 description 2
- 238000002513 implantation Methods 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- 229920002521 macromolecule Polymers 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 210000000066 myeloid cell Anatomy 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 210000001672 ovary Anatomy 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000035790 physiological processes and functions Effects 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 229920000191 poly(N-vinyl pyrrolidone) Polymers 0.000 description 2
- 229920002187 poly[N-2-(hydroxypropyl) methacrylamide] polymer Polymers 0.000 description 2
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 2
- 229920001451 polypropylene glycol Polymers 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 210000001236 prokaryotic cell Anatomy 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- DNIAPMSPPWPWGF-UHFFFAOYSA-N propylene glycol Substances CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 238000004007 reversed phase HPLC Methods 0.000 description 2
- 108091092562 ribozyme Proteins 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 201000011549 stomach cancer Diseases 0.000 description 2
- 230000002194 synthesizing effect Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 150000003573 thiols Chemical class 0.000 description 2
- 229940113082 thymine Drugs 0.000 description 2
- 230000009258 tissue cross reactivity Effects 0.000 description 2
- 229960005267 tositumomab Drugs 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 230000014616 translation Effects 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 238000011269 treatment regimen Methods 0.000 description 2
- 210000004981 tumor-associated macrophage Anatomy 0.000 description 2
- 229940035893 uracil Drugs 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 229920003169 water-soluble polymer Polymers 0.000 description 2
- QCHFTSOMWOSFHM-WPRPVWTQSA-N (+)-Pilocarpine Chemical compound C1OC(=O)[C@@H](CC)[C@H]1CC1=CN=CN1C QCHFTSOMWOSFHM-WPRPVWTQSA-N 0.000 description 1
- FELGMEQIXOGIFQ-CYBMUJFWSA-N (3r)-9-methyl-3-[(2-methylimidazol-1-yl)methyl]-2,3-dihydro-1h-carbazol-4-one Chemical compound CC1=NC=CN1C[C@@H]1C(=O)C(C=2C(=CC=CC=2)N2C)=C2CC1 FELGMEQIXOGIFQ-CYBMUJFWSA-N 0.000 description 1
- VSNHCAURESNICA-NJFSPNSNSA-N 1-oxidanylurea Chemical compound N[14C](=O)NO VSNHCAURESNICA-NJFSPNSNSA-N 0.000 description 1
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- RTQWWZBSTRGEAV-PKHIMPSTSA-N 2-[[(2s)-2-[bis(carboxymethyl)amino]-3-[4-(methylcarbamoylamino)phenyl]propyl]-[2-[bis(carboxymethyl)amino]propyl]amino]acetic acid Chemical compound CNC(=O)NC1=CC=C(C[C@@H](CN(CC(C)N(CC(O)=O)CC(O)=O)CC(O)=O)N(CC(O)=O)CC(O)=O)C=C1 RTQWWZBSTRGEAV-PKHIMPSTSA-N 0.000 description 1
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 1
- SUBDBMMJDZJVOS-UHFFFAOYSA-N 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole Chemical compound N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-UHFFFAOYSA-N 0.000 description 1
- VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 description 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 239000012114 Alexa Fluor 647 Substances 0.000 description 1
- 108020005544 Antisense RNA Proteins 0.000 description 1
- 108010024976 Asparaginase Proteins 0.000 description 1
- 102000015790 Asparaginase Human genes 0.000 description 1
- 208000003950 B-cell lymphoma Diseases 0.000 description 1
- 230000003844 B-cell-activation Effects 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- 238000010354 CRISPR gene editing Methods 0.000 description 1
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 description 1
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 description 1
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 1
- JWBOIMRXGHLCPP-UHFFFAOYSA-N Chloditan Chemical compound C=1C=CC=C(Cl)C=1C(C(Cl)Cl)C1=CC=C(Cl)C=C1 JWBOIMRXGHLCPP-UHFFFAOYSA-N 0.000 description 1
- 208000005590 Choroidal Neovascularization Diseases 0.000 description 1
- 206010060823 Choroidal neovascularisation Diseases 0.000 description 1
- PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
- 108010092160 Dactinomycin Proteins 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- CYQFCXCEBYINGO-DLBZAZTESA-N Dronabinol Natural products C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@H]21 CYQFCXCEBYINGO-DLBZAZTESA-N 0.000 description 1
- 108700034637 EC 3.2.-.- Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 108010029961 Filgrastim Proteins 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- 102000001398 Granzyme Human genes 0.000 description 1
- 108060005986 Granzyme Proteins 0.000 description 1
- 108020005004 Guide RNA Proteins 0.000 description 1
- 101710154606 Hemagglutinin Proteins 0.000 description 1
- 108091027305 Heteroduplex Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101001033249 Homo sapiens Interleukin-1 beta Proteins 0.000 description 1
- 101000971533 Homo sapiens Killer cell lectin-like receptor subfamily G member 1 Proteins 0.000 description 1
- 101000827703 Homo sapiens Polyphosphoinositide phosphatase Proteins 0.000 description 1
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 1
- XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 description 1
- 102000037982 Immune checkpoint proteins Human genes 0.000 description 1
- 108091008036 Immune checkpoint proteins Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000003996 Interferon-beta Human genes 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 108050003558 Interleukin-17 Proteins 0.000 description 1
- 102000013691 Interleukin-17 Human genes 0.000 description 1
- 101710184759 Interleukin-18 receptor 1 Proteins 0.000 description 1
- 102100039340 Interleukin-18 receptor 1 Human genes 0.000 description 1
- 108010002386 Interleukin-3 Proteins 0.000 description 1
- 108010002616 Interleukin-5 Proteins 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- 102100021457 Killer cell lectin-like receptor subfamily G member 1 Human genes 0.000 description 1
- 150000008575 L-amino acids Chemical class 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- HLFSDGLLUJUHTE-SNVBAGLBSA-N Levamisole Chemical compound C1([C@H]2CN3CCSC3=N2)=CC=CC=C1 HLFSDGLLUJUHTE-SNVBAGLBSA-N 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 102000004083 Lymphotoxin-alpha Human genes 0.000 description 1
- 108090000542 Lymphotoxin-alpha Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 108091027974 Mature messenger RNA Proteins 0.000 description 1
- XOGTZOOQQBDUSI-UHFFFAOYSA-M Mesna Chemical compound [Na+].[O-]S(=O)(=O)CCS XOGTZOOQQBDUSI-UHFFFAOYSA-M 0.000 description 1
- 229930192392 Mitomycin Natural products 0.000 description 1
- 101000574441 Mus musculus Alkaline phosphatase, germ cell type Proteins 0.000 description 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- 102220494561 NOP protein chaperone 1_K8Q_mutation Human genes 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 108020003217 Nuclear RNA Proteins 0.000 description 1
- 102000043141 Nuclear RNA Human genes 0.000 description 1
- BZQFBWGGLXLEPQ-UHFFFAOYSA-N O-phosphoryl-L-serine Natural products OC(=O)C(N)COP(O)(O)=O BZQFBWGGLXLEPQ-UHFFFAOYSA-N 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 1
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 208000037581 Persistent Infection Diseases 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 102100023591 Polyphosphoinositide phosphatase Human genes 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 101710176177 Protein A56 Proteins 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 238000003559 RNA-seq method Methods 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 101150036449 SIRPA gene Proteins 0.000 description 1
- QCHFTSOMWOSFHM-UHFFFAOYSA-N SJ000285536 Natural products C1OC(=O)C(CC)C1CC1=CN=CN1C QCHFTSOMWOSFHM-UHFFFAOYSA-N 0.000 description 1
- 108020004459 Small interfering RNA Proteins 0.000 description 1
- 108700005078 Synthetic Genes Proteins 0.000 description 1
- CYQFCXCEBYINGO-UHFFFAOYSA-N THC Natural products C1=C(C)CCC2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3C21 CYQFCXCEBYINGO-UHFFFAOYSA-N 0.000 description 1
- 102100028082 Tapasin Human genes 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 230000001270 agonistic effect Effects 0.000 description 1
- 108700025316 aldesleukin Proteins 0.000 description 1
- 229960005310 aldesleukin Drugs 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229960000473 altretamine Drugs 0.000 description 1
- 230000001668 ameliorated effect Effects 0.000 description 1
- 230000009435 amidation Effects 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- 229960001097 amifostine Drugs 0.000 description 1
- JKOQGQFVAUAYPM-UHFFFAOYSA-N amifostine Chemical compound NCCCNCCSP(O)(O)=O JKOQGQFVAUAYPM-UHFFFAOYSA-N 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 229940121369 angiogenesis inhibitor Drugs 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 101150010487 are gene Proteins 0.000 description 1
- 229960003272 asparaginase Drugs 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-M asparaginate Chemical compound [O-]C(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-M 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 229960001561 bleomycin Drugs 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 229960000455 brentuximab vedotin Drugs 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 229940112129 campath Drugs 0.000 description 1
- 230000009702 cancer cell proliferation Effects 0.000 description 1
- 239000012830 cancer therapeutic Substances 0.000 description 1
- 229960004117 capecitabine Drugs 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- 230000021523 carboxylation Effects 0.000 description 1
- 238000006473 carboxylation reaction Methods 0.000 description 1
- 229960005243 carmustine Drugs 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000022534 cell killing Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 238000011210 chromatographic step Methods 0.000 description 1
- DCSUBABJRXZOMT-IRLDBZIGSA-N cisapride Chemical compound C([C@@H]([C@@H](CC1)NC(=O)C=2C(=CC(N)=C(Cl)C=2)OC)OC)N1CCCOC1=CC=C(F)C=C1 DCSUBABJRXZOMT-IRLDBZIGSA-N 0.000 description 1
- 229960005132 cisapride Drugs 0.000 description 1
- DCSUBABJRXZOMT-UHFFFAOYSA-N cisapride Natural products C1CC(NC(=O)C=2C(=CC(N)=C(Cl)C=2)OC)C(OC)CN1CCCOC1=CC=C(F)C=C1 DCSUBABJRXZOMT-UHFFFAOYSA-N 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 229960002436 cladribine Drugs 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 238000007398 colorimetric assay Methods 0.000 description 1
- 239000003184 complementary RNA Substances 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 150000001945 cysteines Chemical group 0.000 description 1
- 229960000684 cytarabine Drugs 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- 229960003901 dacarbazine Drugs 0.000 description 1
- 229960000640 dactinomycin Drugs 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 230000000779 depleting effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 229950006137 dexfosfoserine Drugs 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 208000037765 diseases and disorders Diseases 0.000 description 1
- 229960003668 docetaxel Drugs 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 229960004242 dronabinol Drugs 0.000 description 1
- VQNATVDKACXKTF-XELLLNAOSA-N duocarmycin Chemical compound COC1=C(OC)C(OC)=C2NC(C(=O)N3C4=CC(=O)C5=C([C@@]64C[C@@H]6C3)C=C(N5)C(=O)OC)=CC2=C1 VQNATVDKACXKTF-XELLLNAOSA-N 0.000 description 1
- 229960005501 duocarmycin Drugs 0.000 description 1
- 229930184221 duocarmycin Natural products 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- 229940082789 erbitux Drugs 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 229960005420 etoposide Drugs 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 229960004177 filgrastim Drugs 0.000 description 1
- 229960000390 fludarabine Drugs 0.000 description 1
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 description 1
- 235000008191 folinic acid Nutrition 0.000 description 1
- 239000011672 folinic acid Substances 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
- 229960005277 gemcitabine Drugs 0.000 description 1
- 229960003297 gemtuzumab ozogamicin Drugs 0.000 description 1
- MFWNKCLOYSRHCJ-BTTYYORXSA-N granisetron Chemical compound C1=CC=C2C(C(=O)N[C@H]3C[C@H]4CCC[C@@H](C3)N4C)=NN(C)C2=C1 MFWNKCLOYSRHCJ-BTTYYORXSA-N 0.000 description 1
- 229960003727 granisetron Drugs 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 201000009277 hairy cell leukemia Diseases 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229940022353 herceptin Drugs 0.000 description 1
- UUVWYPNAQBNQJQ-UHFFFAOYSA-N hexamethylmelamine Chemical compound CN(C)C1=NC(N(C)C)=NC(N(C)C)=N1 UUVWYPNAQBNQJQ-UHFFFAOYSA-N 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 102000057041 human TNF Human genes 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 238000007031 hydroxymethylation reaction Methods 0.000 description 1
- 229960001001 ibritumomab tiuxetan Drugs 0.000 description 1
- 229960000908 idarubicin Drugs 0.000 description 1
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 1
- 229960001101 ifosfamide Drugs 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 230000002584 immunomodulator Effects 0.000 description 1
- 238000013394 immunophenotyping Methods 0.000 description 1
- 229960001438 immunostimulant agent Drugs 0.000 description 1
- 239000003022 immunostimulating agent Substances 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 229960001388 interferon-beta Drugs 0.000 description 1
- 230000014828 interferon-gamma production Effects 0.000 description 1
- 229960004768 irinotecan Drugs 0.000 description 1
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 1
- 229960003174 lansoprazole Drugs 0.000 description 1
- MJIHNNLFOKEZEW-UHFFFAOYSA-N lansoprazole Chemical compound CC1=C(OCC(F)(F)F)C=CN=C1CS(=O)C1=NC2=CC=CC=C2N1 MJIHNNLFOKEZEW-UHFFFAOYSA-N 0.000 description 1
- 229960001691 leucovorin Drugs 0.000 description 1
- 229960001614 levamisole Drugs 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 229960001786 megestrol Drugs 0.000 description 1
- RQZAXGRLVPAYTJ-GQFGMJRRSA-N megestrol acetate Chemical compound C1=C(C)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 RQZAXGRLVPAYTJ-GQFGMJRRSA-N 0.000 description 1
- 229960004635 mesna Drugs 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- TTWJBBZEZQICBI-UHFFFAOYSA-N metoclopramide Chemical compound CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC TTWJBBZEZQICBI-UHFFFAOYSA-N 0.000 description 1
- 229960004503 metoclopramide Drugs 0.000 description 1
- 108091070501 miRNA Proteins 0.000 description 1
- 239000002679 microRNA Substances 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 229960000350 mitotane Drugs 0.000 description 1
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 1
- 229960001156 mitoxantrone Drugs 0.000 description 1
- 210000004985 myeloid-derived suppressor cell Anatomy 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 229960000381 omeprazole Drugs 0.000 description 1
- 229960005343 ondansetron Drugs 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 230000006320 pegylation Effects 0.000 description 1
- 239000000816 peptidomimetic Substances 0.000 description 1
- 210000004976 peripheral blood cell Anatomy 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 229960002087 pertuzumab Drugs 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- BZQFBWGGLXLEPQ-REOHCLBHSA-N phosphoserine Chemical compound OC(=O)[C@@H](N)COP(O)(O)=O BZQFBWGGLXLEPQ-REOHCLBHSA-N 0.000 description 1
- USRGIUJOYOXOQJ-GBXIJSLDSA-N phosphothreonine Chemical compound OP(=O)(O)O[C@H](C)[C@H](N)C(O)=O USRGIUJOYOXOQJ-GBXIJSLDSA-N 0.000 description 1
- DCWXELXMIBXGTH-UHFFFAOYSA-N phosphotyrosine Chemical compound OC(=O)C(N)CC1=CC=C(OP(O)(O)=O)C=C1 DCWXELXMIBXGTH-UHFFFAOYSA-N 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 229960001416 pilocarpine Drugs 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000013823 prenylation Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000013615 primer Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- WIKYUJGCLQQFNW-UHFFFAOYSA-N prochlorperazine Chemical compound C1CN(C)CCN1CCCN1C2=CC(Cl)=CC=C2SC2=CC=CC=C21 WIKYUJGCLQQFNW-UHFFFAOYSA-N 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000001902 propagating effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 235000019419 proteases Nutrition 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 102220289700 rs104894410 Human genes 0.000 description 1
- 102200085424 rs80358242 Human genes 0.000 description 1
- 102220114396 rs886039195 Human genes 0.000 description 1
- 239000010979 ruby Substances 0.000 description 1
- 229910001750 ruby Inorganic materials 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229960001603 tamoxifen Drugs 0.000 description 1
- 108010059434 tapasin Proteins 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 1
- 229960002190 topotecan hydrochloride Drugs 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- 229960002166 vinorelbine tartrate Drugs 0.000 description 1
- GBABOYUKABKIAF-IWWDSPBFSA-N vinorelbinetartrate Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC(C23[C@H]([C@@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-IWWDSPBFSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/60—Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/95—Fusion polypeptide containing a motif/fusion for degradation (ubiquitin fusions, PEST sequence)
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063108794P | 2020-11-02 | 2020-11-02 | |
| US63/108,794 | 2020-11-02 | ||
| PCT/US2021/057741 WO2022094473A1 (en) | 2020-11-02 | 2021-11-02 | Interleukin-18 variants and methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN116723851A true CN116723851A (zh) | 2023-09-08 |
Family
ID=81384408
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202180089105.7A Pending CN116723851A (zh) | 2020-11-02 | 2021-11-02 | 白介素-18变体和使用方法 |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US11850276B2 (https=) |
| EP (1) | EP4236990A4 (https=) |
| JP (1) | JP2023550545A (https=) |
| KR (1) | KR20230117120A (https=) |
| CN (1) | CN116723851A (https=) |
| AR (1) | AR123978A1 (https=) |
| AU (2) | AU2021371040C1 (https=) |
| CA (1) | CA3197145A1 (https=) |
| GB (1) | GB2617483B (https=) |
| IL (1) | IL302517A (https=) |
| MX (1) | MX2023005068A (https=) |
| NZ (1) | NZ800435A (https=) |
| TW (1) | TW202233657A (https=) |
| WO (1) | WO2022094473A1 (https=) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111315395A (zh) | 2017-09-06 | 2020-06-19 | 耶鲁大学 | 白细胞介素-18变体和使用方法 |
| US20230146665A1 (en) | 2021-07-27 | 2023-05-11 | Xencor, Inc. | Il-18-fc fusion proteins |
| WO2023147488A1 (en) | 2022-01-28 | 2023-08-03 | Iovance Biotherapeutics, Inc. | Cytokine associated tumor infiltrating lymphocytes compositions and methods |
| JP2025508823A (ja) | 2022-02-23 | 2025-04-10 | ブライト ピーク セラピューティクス エージー | 免疫抗原特異的ｉｌ－１８免疫サイトカイン及びその使用 |
| WO2024044780A1 (en) * | 2022-08-26 | 2024-02-29 | Sutro Biopharma, Inc. | Interleukin-18 variants and uses thereof |
| JP2025529313A (ja) * | 2022-09-06 | 2025-09-04 | ティージェイ バイオファーマ （シャンハイ） カンパニー， リミテッド | Ｉｌ－１８バリアントポリペプチド |
| US20240166705A1 (en) | 2022-11-07 | 2024-05-23 | Xencor, Inc. | Il18-fc fusion proteins |
| WO2024118836A1 (en) | 2022-11-30 | 2024-06-06 | Iovance Biotherapeutics, Inc. | Processes for production of tumor infiltrating lymphocytes with shortened rep step |
| WO2024158838A2 (en) * | 2023-01-24 | 2024-08-02 | Simcha IL-18, Inc. | Methods and compositions for combination therapy |
| WO2024259270A2 (en) * | 2023-06-16 | 2024-12-19 | Simcha IL-18, Inc. | Administration of engineered interleukin-18 therapeutics |
| AU2024296516A1 (en) | 2023-07-13 | 2026-01-22 | Iovance Biotherapeutics, Inc. | Cytokine encoding lentiviral vectors and uses thereof for making tumor infiltrating lymphocytes |
| US20250188166A1 (en) | 2023-08-23 | 2025-06-12 | Bright Peak Therapeutics Ag | Il-18 polypeptides fused to immune cell antigen specific binding polypeptides and uses thereof |
| WO2025041101A1 (en) | 2023-08-23 | 2025-02-27 | Bright Peak Therapeutics Ag | Activatable il-18 immunocytokines and uses thereof |
| WO2025085447A1 (en) | 2023-10-17 | 2025-04-24 | Xencor, Inc. | Pd-1 targeted il18-fc fusion proteins |
| US20250179137A1 (en) | 2023-12-05 | 2025-06-05 | Regeneron Pharmaceuticals, Inc. | Il18 receptor agonists and methods of use thereof |
| CN120189493A (zh) * | 2023-12-22 | 2025-06-24 | 广州威溶特医药科技有限公司 | Dr-18和m1病毒在制备抗肿瘤药物中的应用 |
| US12134635B1 (en) | 2023-12-29 | 2024-11-05 | Sonnet BioTherapeutics, Inc. | Interleukin 18 (IL-18) variants and fusion proteins comprising same |
| WO2025151273A1 (en) * | 2024-01-08 | 2025-07-17 | Adimab, Llc | Il-18 polypeptides and uses thereof |
| WO2025242835A1 (en) | 2024-05-22 | 2025-11-27 | Ose Immunotherapeutics | Molecules comprising masking linkers and uses thereof for the treatment of cancer |
| WO2026006784A1 (en) | 2024-06-28 | 2026-01-02 | Iovance Biotherapeutics, Inc. | Methods of making tumor reactive peripheral blood lymphocytes (trpbl) |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6156501A (en) | 1993-10-26 | 2000-12-05 | Affymetrix, Inc. | Arrays of modified nucleic acid probes and methods of use |
| EP0816499A3 (en) | 1996-06-27 | 1999-10-27 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | Genomic DNA encoding a polypeptide capable of inducing the production of interferon-gamma |
| JP2007143555A (ja) * | 1996-11-29 | 2007-06-14 | Hayashibara Biochem Lab Inc | ポリペプチド |
| JP4024366B2 (ja) | 1996-11-29 | 2007-12-19 | 株式会社林原生物化学研究所 | ポリペプチド |
| JP3955352B2 (ja) | 1997-02-25 | 2007-08-08 | 株式会社林原生物化学研究所 | 破骨細胞形成阻害剤 |
| TWI227136B (en) | 1998-05-21 | 2005-02-01 | Smithkline Beecham Corp | Novel pharmaceutical composition for the prevention and/or treatment of cancer |
| AU7516601A (en) | 2000-06-02 | 2001-12-17 | Susan B Dillon | Methods of treating viral diseases with il-18 and il-18 combinations |
| ATE315647T1 (de) | 2001-03-08 | 2006-02-15 | Ares Trading Sa | Interleukin -18 mutantenproteine, deren herstellung und verwendung |
| US6800479B2 (en) | 2001-12-11 | 2004-10-05 | Samyang Genex Corporation | Recombinant adenoviruses expressing interleukin-18 protein and gene therapy using them |
| ATE459647T1 (de) * | 2003-04-15 | 2010-03-15 | Glaxosmithkline Llc | Humane il-18 substitutionsmutanten und deren konjugate |
| WO2005075648A1 (en) * | 2004-01-28 | 2005-08-18 | Gifu University | Interleukin-18 mutant proteins |
| JP5916622B2 (ja) * | 2010-01-04 | 2016-05-11 | マピ ファーマ リミテッド | グラチラマーまたはその薬理学的に許容される塩を含むデポーシステム |
| WO2017102010A1 (en) | 2015-12-17 | 2017-06-22 | Biontech Rna Pharmaceuticals Gmbh | Novel cytokine fusion proteins |
| CN111315395A (zh) * | 2017-09-06 | 2020-06-19 | 耶鲁大学 | 白细胞介素-18变体和使用方法 |
| JP2020143000A (ja) * | 2019-03-04 | 2020-09-10 | 大陽日酸株式会社 | 融合タンパク質及びその製造方法、目的タンパク質の製造方法 |
| US12029778B2 (en) * | 2019-05-13 | 2024-07-09 | Yale University | Interleukin-18 mimics and methods of use |
| WO2022038417A2 (en) * | 2020-08-19 | 2022-02-24 | Bright Peak Therapeutics Ag | Modified il-18 polypeptides and uses thereof |
-
2021
- 2021-11-02 TW TW110140842A patent/TW202233657A/zh unknown
- 2021-11-02 KR KR1020237018440A patent/KR20230117120A/ko active Pending
- 2021-11-02 CN CN202180089105.7A patent/CN116723851A/zh active Pending
- 2021-11-02 GB GB2308183.9A patent/GB2617483B/en active Active
- 2021-11-02 AU AU2021371040A patent/AU2021371040C1/en active Active
- 2021-11-02 AR ARP210103038A patent/AR123978A1/es unknown
- 2021-11-02 IL IL302517A patent/IL302517A/en unknown
- 2021-11-02 MX MX2023005068A patent/MX2023005068A/es unknown
- 2021-11-02 NZ NZ800435A patent/NZ800435A/en unknown
- 2021-11-02 JP JP2023551948A patent/JP2023550545A/ja active Pending
- 2021-11-02 CA CA3197145A patent/CA3197145A1/en active Pending
- 2021-11-02 WO PCT/US2021/057741 patent/WO2022094473A1/en not_active Ceased
- 2021-11-02 EP EP21887776.9A patent/EP4236990A4/en active Pending
-
2022
- 2022-12-01 US US18/060,816 patent/US11850276B2/en active Active
-
2023
- 2023-11-03 US US18/501,206 patent/US12582701B2/en active Active
- 2023-11-03 US US18/501,210 patent/US12564621B2/en active Active
-
2025
- 2025-05-12 AU AU2025203386A patent/AU2025203386A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2022094473A1 (en) | 2022-05-05 |
| AU2021371040B2 (en) | 2025-02-13 |
| IL302517A (en) | 2023-07-01 |
| AR123978A1 (es) | 2023-02-01 |
| EP4236990A1 (en) | 2023-09-06 |
| EP4236990A4 (en) | 2025-03-19 |
| TW202233657A (zh) | 2022-09-01 |
| AU2025203386A1 (en) | 2025-06-05 |
| US12564621B2 (en) | 2026-03-03 |
| GB2617483B (en) | 2025-03-12 |
| US20230277625A1 (en) | 2023-09-07 |
| US20240066100A1 (en) | 2024-02-29 |
| AU2021371040C1 (en) | 2025-05-29 |
| NZ800435A (en) | 2025-12-19 |
| CA3197145A1 (en) | 2022-05-05 |
| JP2023550545A (ja) | 2023-12-01 |
| GB2617483A (en) | 2023-10-11 |
| AU2021371040A1 (en) | 2023-06-22 |
| US11850276B2 (en) | 2023-12-26 |
| US20240075104A1 (en) | 2024-03-07 |
| GB202308183D0 (en) | 2023-07-19 |
| MX2023005068A (es) | 2023-07-14 |
| KR20230117120A (ko) | 2023-08-07 |
| US12582701B2 (en) | 2026-03-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12582701B2 (en) | Interleukin-18 variants and methods of use | |
| US12403180B2 (en) | Interleukin-18 variants and methods of use | |
| US11535669B2 (en) | Fusion constructs and methods of using thereof | |
| US12029778B2 (en) | Interleukin-18 mimics and methods of use | |
| EP4556486A1 (en) | Trispecific antibody and use thereof | |
| HK40100300A (zh) | 白介素-18变体和使用方法 | |
| RU2797536C2 (ru) | Варианты интерлейкина-18 и способы их применения | |
| HK40081595B (zh) | 三特异性抗体及其用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40100300 Country of ref document: HK |